Literature DB >> 6314890

In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.

C Watanakunakorn.   

Abstract

The in vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against 50 Pseudomonas aeruginosa strains was studied by the broth dilution method and the time-kill curve method. The majority of the P. aeruginosa strains tested were resistant to ceftriaxone. Combining ceftriaxone with the aminoglycosides resulted in synergism, antagonism, or indifference.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6314890      PMCID: PMC185160          DOI: 10.1128/AAC.24.2.305

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

2.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

3.  Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

4.  Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.

Authors:  P K Yu; R S Edson; J A Washington; P E Hermans
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

5.  Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative.

Authors:  T C Eickhoff; J Ehret
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

  5 in total
  6 in total

1.  Comparison of the serum bactericidal activity of ceftriaxone/piperacillin and ceftriaxone/netilmicin.

Authors:  K Machka; M Röbl; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

2.  Comparative synergistic activity of ceftriaxone-piperacillin versus ceftriaxone-netilmicin.

Authors:  K Machka; R Dietz
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

3.  Association between antimicrobial drug class selection for treatment and retreatment of bovine respiratory disease and health, performance, and carcass quality outcomes in feedlot cattle.

Authors:  Johann F Coetzee; Natalia Cernicchiaro; Pritam K Sidhu; Michael D Kleinhenz
Journal:  J Anim Sci       Date:  2020-04-01       Impact factor: 3.159

4.  Ceftriaxone protects against tobramycin nephrotoxicity.

Authors:  D Beauchamp; G Thériault; L Grenier; P Gourde; S Perron; Y Bergeron; L Fontaine; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 5.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa.

Authors:  K Takahashi; H Kanno
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.